Healthcare Equipment and Supplies
Company Overview of Cognoptix, Inc.
Cognoptix, Inc. operates as a medical technology company that creates and develops a non-invasive eye scanning test for the early detection and diagnosis of Alzheimer’s disease. It also develops combined optical scanning devices and diagnostic agents for clinical, commercial, and academic research use. Cognoptix, Inc. was formerly known as Neuroptix Corporation and changed its name to Cognoptix, Inc. in October 2012. The company was founded in 2001 and is based in Acton, Massachusetts.
20 Main Street
Acton, MA 01720
Founded in 2001
Key Executives for Cognoptix, Inc.
Compensation as of Fiscal Year 2013.
Cognoptix, Inc. Key Developments
Cognoptix Discloses At the 'Clinical Trials on Alzheimer's Disease' Scientific Meeting the Strong Results of Multi-Site Clinical Trial of its SAPPHIRE II Eye Test
Nov 15 13
Cognoptix disclosed at the 'Clinical Trials on Alzheimer's Disease' (CTAD) scientific meeting the strong results of a multi-site clinical trial of its SAPPHIRE II eye test, which is designed to identify Alzheimer's Disease (AD) patients via a beta-amyloid (Ab) signature in their eyes. By detecting a specific fluorescent signature of ligand-marked Ab in the supranucleus region of the human lens, SAPPHIRE II achieved a sensitivity of 85% and a specificity of 95% in differentiating 20 patients who were clinically diagnosed with probable AD from a group of 20 age-matched healthy volunteers. In addition, the SAPPHIRE II test showed excellent correlation to PET (positron emission tomography) amyloid brain imaging.
Cognoptix Announces Results of Multi-Site Clinical Trial of its Sapphire II Eye Test
Sep 23 13
Cognoptix announced the results of a multi-site clinical trial of its SAPPHIRE II eye test designed to identify Alzheimer's disease patients via a beta-amyloid signature in their eyes. By detecting a specific fluorescent signature of ligand-marked Ab in the supranucleus region of the human lens, SAPPHIRE II achieved a sensitivity of 85% and a specificity of 95% in differentiating 20 patients who were clinically diagnosed with probable Alzheimer's Disease from a group of 20 age-matched healthy volunteers. These results validate the previous proof-of-concept clinical trial of the Cognoptix drug/device combination eye test. In addition, the SAPPHIRE II test showed excellent correlation to PET amyloid brain imaging.
Cognoptix, Inc. Eye Test Identifies Alzheimer's Disease in Patients
Jul 15 13
Cognoptix, Inc. announced that it has developed a non-invasive eye-scanning test to identify Alzheimer's. The emerging company said it plans to release data on its Sapphire II eye scanning test - which some say has the potential to transform the way the disease is detected and managed. The technology identifies Alzheimer's disease using a beta amyloid signature in the patient's eyes. According to the company, by detecting a specific fluorescent signature of beta amyloid in the supranucleus region of the human lens, SAPPHIRE II achieved a 200% differentiation factor between a group of five healthy volunteers and a group of five patients diagnosed with probable Alzheimer's disease. The test would help companies researching and developing nearly 100 new Azlheimer's drugs to easily identify patients for clinical studies.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries